<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02572089</url>
  </required_header>
  <id_info>
    <org_study_id>Naloxone-Phase1a-002</org_study_id>
    <nct_id>NCT02572089</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers</brief_title>
  <official_title>Phase 1, Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vince &amp; Associates Clinical Research, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the pharmacokinetics of 4 intranasal doses of naloxone compared to a 0.4 mg dose
      of naloxone administrated intramuscular and to identify an appropriate intranasal dose that
      could achieve systemic exposure comparable to an approved parenteral dose. To also determine
      the pharmacokinetics of two different concentrations of intranasal naloxone and finally, to
      determine the safety of intranasal naloxone with respect to nasal irritation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>720 minutes</time_frame>
    <description>Measurement of serum naloxone prior to dosing and at times 2.5, 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, 360, 480 and 720 minutes after naloxone administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time at Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>720 minutes</time_frame>
    <description>Measurement of serum naloxone prior to dosing and at times 2.5, 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, 360, 480 and 720 minutes after naloxone administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration (AUC 0-t)</measure>
    <time_frame>720 minutes</time_frame>
    <description>Time curve from time zero to last measurable concentration. Measurement of serum naloxone prior to dosing and at times 2.5, 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, 360, 480 and 720 minutes after naloxone administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Curve (AUC 0-inf)</measure>
    <time_frame>720 minutes</time_frame>
    <description>Time curve from time zero to infinity. Measurement of serum naloxone prior to dosing and at times 2.5, 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, 360, 480 and 720 minutes after naloxone administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life</measure>
    <time_frame>720 minutes</time_frame>
    <description>The apparent terminal exponential half-life. Measurement of serum naloxone prior to dosing and at times 2.5, 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, 360, 480 and 720 minutes after naloxone administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>minimum of 18 days</time_frame>
    <description>will be reported from the start of the first session to the follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>480 minutes</time_frame>
    <description>Measured at pre-dose and at times 30 , 60, 120 and 480 minutes after naloxone administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead electrocardiogram</measure>
    <time_frame>480 minutes</time_frame>
    <description>Measured at pre-dose and at times 60 and 480 minutes after naloxone administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Irritation Scoring</measure>
    <time_frame>24 hours</time_frame>
    <description>Measured at pre-dose and at times 5, 30 , 60, 240 minutes and 24 hours after nasal naloxone administration.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Drug Overdose</condition>
  <condition>Opioid-Related Disorders</condition>
  <arm_group>
    <arm_group_label>2mg Intranasal Naloxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer 0.1mL spray of the 20 mg/mL formulation in one nostril</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4mg(a) Intranasal Naloxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer 0.1mL spray of the 20 mg/mL formulation in both nostrils</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4mg(b) Intranasal Naloxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer 0.1mL spray of the 40mg/mL formulation in one nostril</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8mg Intranasal Naloxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer 0.1mL spray of the 40mg/mL formulation in both nostrils</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular Naloxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer 1mL of 0.4mg/mL formulation intramuscularly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone</intervention_name>
    <arm_group_label>2mg Intranasal Naloxone</arm_group_label>
    <arm_group_label>4mg(a) Intranasal Naloxone</arm_group_label>
    <arm_group_label>4mg(b) Intranasal Naloxone</arm_group_label>
    <arm_group_label>8mg Intranasal Naloxone</arm_group_label>
    <arm_group_label>Intramuscular Naloxone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be able to provide written consent

          -  Must have a BMI ranging from 18 to 30kg/m2, inclusive

          -  Must have adequate venous access

          -  Must not have any clinically significant concurrent medical conditions determine by
             medical history, physical examination, vital signs, and 12-lead electrocardiogram.

          -  Must agree to use a reliable double-barrier method of birth control from the start of
             screening until one week after completing the study. Oral contraceptives are
             prohibited.

          -  Must agree to not ingest alcohol, drinks containing xanthine greater than 500 mg/day
             (e.g., Coca Cola, coffee, tea, etc.), or grapefruit/grapefruit juice or participate in
             strenuous exercise 72 hours prior to admission through the last blood draw of the
             study.

        Exclusion Criteria:

          -  Please contact clinical site directly for more information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vince Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2015</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Drug Overdose</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

